Beta-Blocker Therapy in Severe Traumatic Brain Injury: A Prospective Randomized Controlled Trial.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 1 2 2020
medline: 26 1 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Observational studies have demonstrated improved outcomes in TBI patients receiving in-hospital beta-blockers. The aim of this study is to conduct a randomized controlled trial examining the effect of beta-blockers on outcomes in TBI patients. Adult patients with severe TBI (intracranial AIS ≥ 3) were included in the study. Hemodynamically stable patients at 24 h after injury were randomized to receive either 20 mg propranolol orally every 12 h up to 10 days or until discharge (BB+) or no propranolol (BB-). Outcomes of interest were in-hospital mortality and Glasgow Outcome Scale-Extended (GOS-E) score on discharge and at 6-month follow-up. Subgroup analysis including only isolated severe TBI (intracranial AIS ≥ 3 with extracranial AIS ≤ 2) was carried out. Poisson regression models were used. Two hundred nineteen randomized patients of whom 45% received BB were analyzed. There were no significant demographic or clinical differences between BB Propranolol decreases in-hospital mortality and improves long-term functional outcome in isolated severe TBI. This randomized trial speaks in favor of routine administration of beta-blocker therapy as part of a standardized neurointensive care protocol. Level II; therapeutic. Therapeutic study.

Sections du résumé

BACKGROUND
Observational studies have demonstrated improved outcomes in TBI patients receiving in-hospital beta-blockers. The aim of this study is to conduct a randomized controlled trial examining the effect of beta-blockers on outcomes in TBI patients.
METHODS
Adult patients with severe TBI (intracranial AIS ≥ 3) were included in the study. Hemodynamically stable patients at 24 h after injury were randomized to receive either 20 mg propranolol orally every 12 h up to 10 days or until discharge (BB+) or no propranolol (BB-). Outcomes of interest were in-hospital mortality and Glasgow Outcome Scale-Extended (GOS-E) score on discharge and at 6-month follow-up. Subgroup analysis including only isolated severe TBI (intracranial AIS ≥ 3 with extracranial AIS ≤ 2) was carried out. Poisson regression models were used.
RESULTS
Two hundred nineteen randomized patients of whom 45% received BB were analyzed. There were no significant demographic or clinical differences between BB
CONCLUSION
Propranolol decreases in-hospital mortality and improves long-term functional outcome in isolated severe TBI. This randomized trial speaks in favor of routine administration of beta-blocker therapy as part of a standardized neurointensive care protocol.
LEVEL OF EVIDENCE
Level II; therapeutic.
STUDY TYPE
Therapeutic study.

Identifiants

pubmed: 32002583
doi: 10.1007/s00268-020-05391-8
pii: 10.1007/s00268-020-05391-8
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Propranolol 9Y8NXQ24VQ

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1844-1853

Commentaires et corrections

Type : CommentIn

Références

Am Surg. 2008 Sep;74(9):866-72
pubmed: 18807680
Nature. 1975 Dec 4;258(5534):437-40
pubmed: 620
J Head Trauma Rehabil. 2010 Mar-Apr;25(2):72-80
pubmed: 20234226
Lancet. 2000 Sep 9;356(9233):923-9
pubmed: 11036909
J Trauma Acute Care Surg. 2012 Jul;73(1):33-40
pubmed: 22743370
Neurocrit Care. 2014 Jun;20(3):514-23
pubmed: 24062229
Neuroscience. 2014 Dec 26;283:245-55
pubmed: 24973658
J Trauma. 1993 Feb;34(2):216-22
pubmed: 8459458
Stroke. 1974 Mar-Apr;5(2):180-95
pubmed: 4816133
J Surg Res. 2016 Jan;200(1):221-6
pubmed: 26188959
J Trauma Acute Care Surg. 2018 Feb;84(2):234-244
pubmed: 29251711
J Neurosurg. 1992 Dec;77(6):901-7
pubmed: 1432133
J Crit Care. 2017 Oct;41:240-246
pubmed: 28595083
Neurosurgery. 1981 Jan;8(1):10-4
pubmed: 7207763
J Trauma Acute Care Surg. 2016 Apr;80(4):637-42
pubmed: 26808028
J Trauma. 2009 Jan;66(1):154-9; discussion 159-61
pubmed: 19131818
J Trauma. 2010 Dec;69(6):1602-9
pubmed: 21045744
Eur J Trauma Emerg Surg. 2017 Dec;43(6):783-789
pubmed: 28275834
J Trauma Acute Care Surg. 2014 Mar;76(3):804-8
pubmed: 24553552
Arch Surg. 2001 Oct;136(10):1118-23
pubmed: 11585502
Lancet. 1987 Sep 12;2(8559):585-9
pubmed: 2887885
J Trauma. 2007 Jan;62(1):26-33; discussion 33-5
pubmed: 17215730
Circ Res. 2017 Aug 4;121(4):451-468
pubmed: 28775014
Ann Surg. 2017 Dec;266(6):952-961
pubmed: 28525411
Am J Physiol. 1976 Aug;231(2):489-94
pubmed: 961902
Am Heart J. 1969 Aug;78(2):145-8
pubmed: 5797266
Ann Neurol. 1987 May;21(5):438-43
pubmed: 3592639

Auteurs

Hosseinali Khalili (H)

Department of Neurosurgery, Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Rebecka Ahl (R)

Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.
School of Medical Sciences, Orebro University, 702 81, Örebro, Sweden.

Shahram Paydar (S)

Trauma Research Center, Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.

Gabriel Sjolin (G)

Department of Surgery, Orebro University Hospital, 701 85, Örebro, Sweden.
School of Medical Sciences, Orebro University, 702 81, Örebro, Sweden.

Yang Cao (Y)

Clinical Epidemiology and Biostatistics, School of Medical Sciences, Orebro University, 701 82, Örebro, Sweden.

Hossein Abdolrahimzadeh Fard (H)

Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.
Trauma Research Center, Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Amin Niakan (A)

Department of Neurosurgery, Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Kamil Hanna (K)

Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.

Bellal Joseph (B)

Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.

Shahin Mohseni (S)

School of Medical Sciences, Orebro University, 702 81, Örebro, Sweden. mohsenishahin@yahoo.com.
Division of Trauma and Emergency Surgery, Department of Surgery, Orebro University Hospital, 701 85, Örebro, Sweden. mohsenishahin@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH